Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma

Koji Matsuo, Malcolm S. Ross, Mayu Yunokawa, Marian S. Johnson, Hiroko Machida, Kohei Omatsu, Merieme M. Klobocista, Dwight D. Im, Shinya Satoh, Tsukasa Baba, Yuji Ikeda, Stephen H. Bush, Kosei Hasegawa, Erin A. Blake, Munetaka Takekuma, Masako Shida, Masato Nishimura, Sosuke Adachi, Tanja Pejovic, Satoshi TakeuchiTakuhei Yokoyama, Yutaka Ueda, Keita Iwasaki, Takahito M. Miyake, Shiori Yanai, Tadayoshi Nagano, Tadao Takano, Mian M.K. Shahzad, Frederick R. Ueland, Joseph L. Kelley, Lynda D. Roman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To examine survival after recurrence (SAR) among women with recurrent uterine carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods: We retrospectively examined 148 women with recurrent uterine carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results: There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P <. 0.001). On multivariate analysis, use of taxane/platinum regimen was independently associated with improved SAR compared to the non-taxane/platinum regimens (adjusted-hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.35 to 0.91, P = 0.02). When stratified by disease-free interval, women with a disease-free interval ≥. 6. months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P = 0.002); conversely, in women with a disease-free interval <. 6. months, 2-year SAR rates were similar between the two groups (20.5% versus 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P = 0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1% versus 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P = 0.019). Conclusion: Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine carcinosarcoma, especially for those who had a disease-free interval of ≥. 6. months.

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StateAccepted/In press - 2017

Fingerprint

Carcinosarcoma
Platinum
Drug Therapy
Recurrence
Survival
Confidence Intervals
taxane
Multivariate Analysis
Adjuvant Chemotherapy

Keywords

  • Chemotherapy
  • Platinum
  • Recurrence
  • Survival outcome
  • Taxane
  • Uterine carcinosarcoma

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Matsuo, K., Ross, M. S., Yunokawa, M., Johnson, M. S., Machida, H., Omatsu, K., ... Roman, L. D. (Accepted/In press). Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2017.10.008

Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. / Matsuo, Koji; Ross, Malcolm S.; Yunokawa, Mayu; Johnson, Marian S.; Machida, Hiroko; Omatsu, Kohei; Klobocista, Merieme M.; Im, Dwight D.; Satoh, Shinya; Baba, Tsukasa; Ikeda, Yuji; Bush, Stephen H.; Hasegawa, Kosei; Blake, Erin A.; Takekuma, Munetaka; Shida, Masako; Nishimura, Masato; Adachi, Sosuke; Pejovic, Tanja; Takeuchi, Satoshi; Yokoyama, Takuhei; Ueda, Yutaka; Iwasaki, Keita; Miyake, Takahito M.; Yanai, Shiori; Nagano, Tadayoshi; Takano, Tadao; Shahzad, Mian M.K.; Ueland, Frederick R.; Kelley, Joseph L.; Roman, Lynda D.

In: Gynecologic Oncology, 2017.

Research output: Contribution to journalArticle

Matsuo, K, Ross, MS, Yunokawa, M, Johnson, MS, Machida, H, Omatsu, K, Klobocista, MM, Im, DD, Satoh, S, Baba, T, Ikeda, Y, Bush, SH, Hasegawa, K, Blake, EA, Takekuma, M, Shida, M, Nishimura, M, Adachi, S, Pejovic, T, Takeuchi, S, Yokoyama, T, Ueda, Y, Iwasaki, K, Miyake, TM, Yanai, S, Nagano, T, Takano, T, Shahzad, MMK, Ueland, FR, Kelley, JL & Roman, LD 2017, 'Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma', Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2017.10.008
Matsuo, Koji ; Ross, Malcolm S. ; Yunokawa, Mayu ; Johnson, Marian S. ; Machida, Hiroko ; Omatsu, Kohei ; Klobocista, Merieme M. ; Im, Dwight D. ; Satoh, Shinya ; Baba, Tsukasa ; Ikeda, Yuji ; Bush, Stephen H. ; Hasegawa, Kosei ; Blake, Erin A. ; Takekuma, Munetaka ; Shida, Masako ; Nishimura, Masato ; Adachi, Sosuke ; Pejovic, Tanja ; Takeuchi, Satoshi ; Yokoyama, Takuhei ; Ueda, Yutaka ; Iwasaki, Keita ; Miyake, Takahito M. ; Yanai, Shiori ; Nagano, Tadayoshi ; Takano, Tadao ; Shahzad, Mian M.K. ; Ueland, Frederick R. ; Kelley, Joseph L. ; Roman, Lynda D. / Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. In: Gynecologic Oncology. 2017.
@article{92182c019d2f4ce88d1dcc05807c3ff0,
title = "Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma",
abstract = "Objective: To examine survival after recurrence (SAR) among women with recurrent uterine carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods: We retrospectively examined 148 women with recurrent uterine carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results: There were 71 (48.0{\%}) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5{\%} versus 34.8{\%}, P <. 0.001). On multivariate analysis, use of taxane/platinum regimen was independently associated with improved SAR compared to the non-taxane/platinum regimens (adjusted-hazard ratio [HR] 0.56, 95{\%} confidence interval [CI] 0.35 to 0.91, P = 0.02). When stratified by disease-free interval, women with a disease-free interval ≥. 6. months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9{\%} versus 40.0{\%}, HR 0.46, 95{\%} CI 0.28 to 0.75, P = 0.002); conversely, in women with a disease-free interval <. 6. months, 2-year SAR rates were similar between the two groups (20.5{\%} versus 18.4{\%}, HR 0.80, 95{\%} CI 0.33 to 1.90, P = 0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1{\%} versus 39.7{\%}, HR 0.40, 95{\%} CI 0.18 to 0.86, P = 0.019). Conclusion: Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine carcinosarcoma, especially for those who had a disease-free interval of ≥. 6. months.",
keywords = "Chemotherapy, Platinum, Recurrence, Survival outcome, Taxane, Uterine carcinosarcoma",
author = "Koji Matsuo and Ross, {Malcolm S.} and Mayu Yunokawa and Johnson, {Marian S.} and Hiroko Machida and Kohei Omatsu and Klobocista, {Merieme M.} and Im, {Dwight D.} and Shinya Satoh and Tsukasa Baba and Yuji Ikeda and Bush, {Stephen H.} and Kosei Hasegawa and Blake, {Erin A.} and Munetaka Takekuma and Masako Shida and Masato Nishimura and Sosuke Adachi and Tanja Pejovic and Satoshi Takeuchi and Takuhei Yokoyama and Yutaka Ueda and Keita Iwasaki and Miyake, {Takahito M.} and Shiori Yanai and Tadayoshi Nagano and Tadao Takano and Shahzad, {Mian M.K.} and Ueland, {Frederick R.} and Kelley, {Joseph L.} and Roman, {Lynda D.}",
year = "2017",
doi = "10.1016/j.ygyno.2017.10.008",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma

AU - Matsuo, Koji

AU - Ross, Malcolm S.

AU - Yunokawa, Mayu

AU - Johnson, Marian S.

AU - Machida, Hiroko

AU - Omatsu, Kohei

AU - Klobocista, Merieme M.

AU - Im, Dwight D.

AU - Satoh, Shinya

AU - Baba, Tsukasa

AU - Ikeda, Yuji

AU - Bush, Stephen H.

AU - Hasegawa, Kosei

AU - Blake, Erin A.

AU - Takekuma, Munetaka

AU - Shida, Masako

AU - Nishimura, Masato

AU - Adachi, Sosuke

AU - Pejovic, Tanja

AU - Takeuchi, Satoshi

AU - Yokoyama, Takuhei

AU - Ueda, Yutaka

AU - Iwasaki, Keita

AU - Miyake, Takahito M.

AU - Yanai, Shiori

AU - Nagano, Tadayoshi

AU - Takano, Tadao

AU - Shahzad, Mian M.K.

AU - Ueland, Frederick R.

AU - Kelley, Joseph L.

AU - Roman, Lynda D.

PY - 2017

Y1 - 2017

N2 - Objective: To examine survival after recurrence (SAR) among women with recurrent uterine carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods: We retrospectively examined 148 women with recurrent uterine carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results: There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P <. 0.001). On multivariate analysis, use of taxane/platinum regimen was independently associated with improved SAR compared to the non-taxane/platinum regimens (adjusted-hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.35 to 0.91, P = 0.02). When stratified by disease-free interval, women with a disease-free interval ≥. 6. months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P = 0.002); conversely, in women with a disease-free interval <. 6. months, 2-year SAR rates were similar between the two groups (20.5% versus 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P = 0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1% versus 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P = 0.019). Conclusion: Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine carcinosarcoma, especially for those who had a disease-free interval of ≥. 6. months.

AB - Objective: To examine survival after recurrence (SAR) among women with recurrent uterine carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. Methods: We retrospectively examined 148 women with recurrent uterine carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. Results: There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P <. 0.001). On multivariate analysis, use of taxane/platinum regimen was independently associated with improved SAR compared to the non-taxane/platinum regimens (adjusted-hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.35 to 0.91, P = 0.02). When stratified by disease-free interval, women with a disease-free interval ≥. 6. months who received a taxane/platinum doublet had a higher 2-year SAR rate compared to those who received non-taxane/platinum regimens (61.9% versus 40.0%, HR 0.46, 95% CI 0.28 to 0.75, P = 0.002); conversely, in women with a disease-free interval <. 6. months, 2-year SAR rates were similar between the two groups (20.5% versus 18.4%, HR 0.80, 95% CI 0.33 to 1.90, P = 0.61). Among women who received a taxane/platinum doublet as adjuvant chemotherapy, re-treatment with taxane/platinum doublet as salvage chemotherapy remained beneficial (2-year SAR rate, 62.1% versus 39.7%, HR 0.40, 95% CI 0.18 to 0.86, P = 0.019). Conclusion: Our study suggests that taxane/platinum doublet may be a more effective chemotherapy regimen compared to other regimens among women with recurrent uterine carcinosarcoma, especially for those who had a disease-free interval of ≥. 6. months.

KW - Chemotherapy

KW - Platinum

KW - Recurrence

KW - Survival outcome

KW - Taxane

KW - Uterine carcinosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85031742495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031742495&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.10.008

DO - 10.1016/j.ygyno.2017.10.008

M3 - Article

C2 - 29056442

AN - SCOPUS:85031742495

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -